Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ortho-Clinical Diagnostics, Inc.
A prospective clinical sample collection and NT-proBNP testing will be conducted in two populations. Patients presenting to the Emergency Department (ED) and patients presenting to outpatient centers will be approached for enrollment.
Clinical and laboratory data will be collected to demonstrate product performance compared to adjudicated clinical diagnosis. Approximately 4300 evaluable subjects at geographically dispersed sites in the US will be enrolled in the study.
Sample collection and testing of clinical samples with the VITROS NT-proBNP II assay will be performed under two separate protocols.
Age
22–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Acute HF Population (ED setting):
Subjects must have suspicion of HF and acute symptoms at presentation.
Subjects must be at least 22 years of age.
Subjects must be willing and able to provide informed consent.
Subjects must be at least 22 years of age.
Subjects must be willing and able to provide informed consent.
Subjects who present to outpatient centers with suspicion HF.
You may not be if
Acute symptoms clearly not secondary to HF.
Subjects with renal disease on dialysis.
Subjects unable to comply with the study requirements.
Population with suspicion of HF (Outpatient Setting):
Symptoms clearly not secondary to HF.
Subjects with renal disease on dialysis.
Subjects unable to comply with the study requirements.
Subjects previously diagnosed with heart failure.
Clareo Health | VITROS Immunodiagnostic Products NT-proBNP II
